Neuropathy clinical trials at UCSF
2 in progress, 1 open to eligible people
Two Dose Levels of Privigen in Pediatric CIDP
open to eligible people ages 2-17
A randomized, open-label, prospective, multicenter study designed to investigate 2 dose levels in pediatric subjects 2 to ≤ 17 years of age with confirmed or possible CIDP, either previously exposed to IVIG treatment or unexposed to IVIG treatment
San Francisco, California and other locations
NA-AION Risk Factors: New Perspectives
Sorry, not currently recruiting here
The purpose of the study is to use new diagnostic methods (OCT and OCT-A) to shed light on risk factors for the development of NA-AION. The risk factors we are focusing on are comorbidities along with anatomical and vascular characteristics of the optic nerve.
San Francisco, California and other locations
Our lead scientists for Neuropathy research studies include Jonathan Strober Nailyn Rasool.
Last updated: